Purpose: A new scoring system named “six- and twelve score” was presented by Wang et al. for prediction of the overall survival in hepatocellular carcinoma (HCC) patients mostly due to hepatitis B virus (HBV) treated with transarterial chemoembolization (TACE). This scoring system is calculated by sum of the tumor size and number. It divides the patients into 3 groups, G1 ≤6, G2 >6 but ≤12, and G3 >12 with median overall survival 49.1 months, 32.0 months, and 15.8 months respectively. Our aim is to assess the prognostic value of this scoring system in HCC patients due to hepatitis C virus (HCV) treated with TACE in our center.
Material and Methods: A total of 79 HCV positive-patients with HCC treated with TACE were included in this study with the same inclusion and exclusion criteria of the six- and twelve score study. According to this scoring system we divided our patients into 3 groups; G1 (24 patients), G2 (31 patients) and G3 (24 patients). We followed up our patients to assess the overall survival rate.
Results: Mean overall survival rate at 3 years was 32 months for G1, 21 months for G2 and 10 months for G3.
Conclusions: Our data suggests that six and twelve score could not be applicable for prediction of overall survival in HCV patients with HCC treated with TACE. Further studies are recommended to validate this scoring system in prediction of survival in HCC patients with HCV.
